Abstract:Abstract ASP2074 is a novel bispecific antibody that targets the tumor-associated antigen tetraspanin 8 (TSPAN8) and CD3, which is expressed on the plasma membrane of all T cells. By engaging with both TSPAN8 and CD3, ASP2074 enables the retargeting of cytotoxic T cells specifically against TSPAN8-expressing tumor cells in a human leukocyte antigen-independent manner. TSPAN8 is a member of the tetraspanin superfamily of proteins that plays a crucial role in intracellular signal transduction and regulates various cellular functions, including leukocyte trafficking, angiogenesis, and wound repair. TSPAN8 is highly expressed in various types of cancer, such as colorectal cancer, gastric cancer, pancreatic cancer, esophageal adenocarcinoma, and gastroesophageal junction (GEJ) adenocarcinoma. Its overexpression has been associated with tumor cell growth, angiogenesis, invasion, metastasis, and poor prognosis, making it an attractive target for antibody-based cancer immunotherapy. ASP2074 is currently undergoing phase 1 clinical trials for the treatment of patients with colorectal cancer, esophageal adenocarcinoma, pancreatic cancer, gastric cancer, and GEJ adenocarcinoma. In this study, we examined the selectivity and antitumor activity of ASP2074 in vitro and in vivo. Methods: Retrogenix Cell Microarray Technology was used to evaluate the selective binding of ASP2074 to TSPAN8 and CD3 in 6018 full-length human plasma membrane proteins, secreted and cell surface-tethered human secreted proteins, and 397 human heterodimers containing homologs and isoforms of tetraspanin. Cytotoxicity and T-cell activation of ASP2074 were examined using TSPAN8-expressing tumor cells in combination with human peripheral blood mononuclear cells (PBMCs) as effector cells in a redirected T-cell cytotoxicity assay. Furthermore, the antitumor effect of ASP2074 was examined in a human PBMC-engrafted NOG mouse model bearing human TSPAN8-expressing colorectal cancer cells. Results: Our results showed that ASP2074 selectively bound to TSPAN8 and CD3 without significant binding to other human plasma membrane proteins, secreted proteins, and heterodimers. ASP2074 exhibited cytotoxicity against TSPAN8-expressing cancer cells and increased interferon-gamma production and expression of T-cell activation markers. The cytotoxic activities were dependent on the TSPAN8 expression levels in tumor cells. In the NOG mouse model, ASP2074 exhibited an antitumor effect on human TSPAN8-expressing colorectal cancer cells in vivo. Conclusion: Our findings suggest that ASP2074 has potent antitumor activity through cytotoxicity against TSPAN8-expressing tumor cells by T-cell activation via selective binding to TSPAN8 and CD3. These preclinical results support the continued development of ASP2074 as a promising immunotherapy for the treatment of TSPAN8-expressing cancers. Citation Format: Yoshiyuki Tenda, Yuichi Hanada, Hiroaki Tanaka, Masashi Shimazaki, Kenna Shirasuna. ASP2074, a novel tetraspanin 8 x CD3 bispecific antibody, demonstrates selectivity and antitumor activity in preclinical cancer models [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A173.

Characterization of a Novel Recombinant Calcium-Binding Protein from Arca Subcrenata and Its Anti-Hepatoma Activities in Vitro and in Vivo.

Identification and Characterization of a Novel Protein ASP-3 Purified from Arca Subcrenata and Its Antitumor Mechanism

Characterization of a Novel Polysaccharide from Arca Subcrenata and Its Immunoregulatory Activities in Vitro and in Vivo.

HJC0152, a Novel STAT3 Inhibitor with Promising Anti-Tumor Effect in Gastric Cancer

FP3: a Novel VEGF Blocker with Anti-Angiogenic and Anti-Tumor Effects.

Antitumor Effect of FP3 on a Patient-Derived Tumor Tissue Xenograft Model of Rectal Carcinoma.

Asperulosidic Acid Restrains Hepatocellular Carcinoma Development and Enhances Chemosensitivity Through Inactivating the MEKK1/NF-κB Pathway

Arctigenin Attenuates Tumor Metastasis Through Inhibiting Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma Via Suppressing GSK3β-Dependent Wnt/β-Catenin Signaling Pathway in Vivo and in Vitro

A New in Vitro Anti-Tumor Polypeptide Isolated from Arca inflata

A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel

A New Antiproliferative And Antioxidant Peptide Isolated From Arca Subcrenata

Anticancer Efficacy and Absorption, Distribution, Metabolism, and Toxicity Studies of Aspergiolide A in Early Drug Development

Inhibitory Effect of Recombinant Adenovirus Carrying Immunocaspase-3 on Hepatocellular Carcinoma

33-kDa ANXA3 Knockdown Suppresses Carcinogenesis, Angiogenesis and Enhances Chemoresistance of Hepatocarcinoma via Inhibiting ERK, PI3K/Akt-HIF and Intrinsic Apoptosis Pathways

Abstract A173: ASP2074, a novel tetraspanin 8 x CD3 bispecific antibody, demonstrates selectivity and antitumor activity in preclinical cancer models

3′‐Desmethylarctigenin Induces G2/M Cell Cycle Arrest and Apoptosis Through Reactive Oxygen Species Generation in Hepatocarcinoma Cells

Abstract 6019: Biodistribution, molecular imaging and efficacy evaluation of a novel GPC3-targeted radiopharmaceutical therapy for hepatocellular carcinoma

Rheum Palmatum Extract Exerts Anti-Hepatocellular Carcinoma Effects by Inhibiting Signal Transducer and Activator of Transcription 3 Signaling.

Abstract 3805: Anticancer Agent HJC0416 Inhibits the Growth of Breast Cancer Xenografts Via Downregulating STAT3 Signaling

Efficacy of Annexin A3 Blockade in Sensitizing Hepatocellular Carcinoma to Sorafenib and Regorafenib.

3'-Desmethylarctigenin induces G2/M cell cycle arrest and apoptosis through reactive oxygen species generation in hepatocarcinoma cells.